Brainomix, a leader in AI imaging solutions for precision medicine, proudly announces the FDA clearance of its newest offering, Brainomix 360 e-Lung.
This expansion into lung imaging comes on the heels of the widespread adoption of its Brainomix 360 Stroke platform in both the US and Europe.
Brainomix announces the FDA clearance of its latest product, Brainomix 360 e-Lung, marking its entry into lung imaging. This follows the success of its Brainomix 360 Stroke platform.
The clearance of e-Lung signifies a significant milestone for Brainomix, reflecting its commitment to advancing medical imaging. With a strong academic background, Brainomix will expand its research collaborations in pulmonology to further develop e-Lung.
The company expansion into the lung space, highlighting the potential of e-Lung to improve healthcare delivery and patient outcomes.
Brainomix recently collaborated with AstraZeneca on a study published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), demonstrating the effectiveness of its lung imaging biomarkers in stratifying patients at risk of Idiopathic Pulmonary Fibrosis (IPF) progression.
The company's commitment to developing innovative solutions beyond stroke. The FDA clearance of e-Lung underscores Brainomix's dedication to providing healthcare professionals with advanced tools for precise disease evaluation and improving patient outcomes.
Source: https://www.prnewswire.com/news-releases/brainomix-achieves-breakthrough-with-fda-clearance-of-e-lung-ai-software-302144832.html
